Black Pepper Extract (BioPerine).

Curcumin is broken down and cleared so quickly by gut and liver enzymes that very little normally reaches the bloodstream on its own. Piperine slows that glucuronidation step, so much more of the curcumin you take stays in circulation, which is why the two are nearly always formulated together.

Curcuminoids are almost entirely glucuronidated and sulfated on first pass, and piperine inhibits those intestinal and hepatic enzymes. This is the original and most documented use of the pairing.

Piperine slows the UGT-mediated conjugation that removes curcuminoids during absorption. Circulating curcuminoid levels rise several fold from the same oral dose.

Resveratrol is limited almost entirely by rapid glucuronidation and sulfation in the gut wall and liver. Piperine inhibits those enzymes, so more free resveratrol reaches circulation.

CoQ10 is a large lipophilic molecule with poor and variable uptake. Piperine is used in CoQ10 formulations to raise the absorbed fraction, and the standardised extract has been characterised for that effect.

EGCG is heavily glucuronidated and methylated during absorption, which caps its exposure. Piperine slows that first-pass conjugation and raises circulating catechin levels.

Quercetin is cleared mainly by intestinal glucuronidation and sulfation. Inhibiting those enzymes with piperine leaves more of the aglycone available for absorption.

Berberine's low oral bioavailability comes largely from P-glycoprotein pumping it back into the gut lumen. Piperine inhibits P-glycoprotein, which raises berberine exposure and means dosing should account for that.

Piperine increases the intestinal uptake of carotenoids, an effect measured directly with beta carotene. The same oral dose produces higher plasma levels.

The standardised piperine extract has been characterised for raising selenium absorption, attributed to effects on intestinal transport and enterocyte membrane fluidity.

Piperine has been characterised for increasing uptake of water-soluble vitamins including pyridoxine, attributed to altered enterocyte membrane dynamics and slower gut transit.

Piperine raises intestinal permeability and mineral uptake, and iron is one of the minerals characterised for that effect. Dose accounting matters because uptake shifts upward.

Long pepper also owes its activity to piperine, so combining the two stacks the same alkaloid rather than adding a new mechanism. Total piperine load is what needs watching.

Black pepper, long pepper and ginger form the classical trikatu combination used with other botanicals. Ginger also slows gastric emptying, which lengthens the absorption window.

Boswellic acids have low and variable oral uptake driven by efflux and rapid conjugation. Piperine acts on both, which is why it appears in boswellia formulations.

Lycopene shares the micellar uptake and enterocyte processing route that piperine acts on. No human piperine plus lycopene measurement is available in this record. The mechanism is the claim; the magnitude is not.

Astaxanthin absorption is limited by micelle formation and by efflux back into the lumen, both of which piperine has been shown to influence for other substrates. Nothing in the available literature measures the pair. It sits in formulas on mechanistic grounds.

EGCG plasma exposure is short because glucuronidation and methylation clear it quickly. Piperine inhibits UGT activity in intestinal and hepatic preparations, and preclinical work using this pair reports higher EGCG exposure. Human confirmation of the size of that shift is not in the candidate set.

Pterostilbene resists first-pass conjugation better than resveratrol but is still glucuronidated. Piperine's inhibition of that step is the reason the two appear together. No dedicated human pharmacokinetic pairing is cited here.

Silybin exposure after oral dosing is low largely because conjugation removes it before it reaches circulation. Piperine acts on that same conjugation step for other substrates, which is the stated rationale for co-formulation. The pairing has not been measured in the papers available here.

Piperine itself dissolves in oil far better than in water, and so do most of the compounds it is paired with. A lipid vehicle raises the fraction that ends up in mixed micelles and available for uptake. This is formulation chemistry rather than a claimed physiological interaction.

Ayurvedic formulation uses pungent enhancers alongside botanical actives, and modern products carry that pattern forward with standardised piperine. Withanolide pharmacokinetics with piperine have not been characterised in the literature available here. The row records the practice, not a measured gain.

In rodent work piperine stimulates bile and pancreatic secretion and lengthens transit time, both of which extend contact time for luminal digestion. Whether that adds anything to a supplemental enzyme blend in people has not been measured. Read this as a preclinical mechanism, not a human effect.

Hypericum constituents raise CYP3A4 and P-glycoprotein expression over days to weeks, and piperine inhibits the activity of the same two systems acutely. Combining them makes the exposure of anything else in the formula unpredictable, since one arm is turning capacity up and the other is turning activity down. Flagged because the interaction direction is textbook even though the pair has not been studied together.

Piperine is a common addition to caffeine-containing thermogenic blends on the reasoning that it slows clearance of co-ingested actives. Caffeine is cleared mainly by CYP1A2, where piperine's effect is less characterised than at CYP3A4. Any additive stimulant sensation should be counted as unquantified.